Noticias y Actividades de Teva Europe

Teva Europe pertenece a Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries es una de las ...

• Forbes Global 2000 (#935);
• TOB Iconic 10,000.

Teva Pharmaceutical Industries es una empresa que cotiza bajo el símbolo de cotización TEVA (IL).

Teva Pharmaceutical Industries tiene presencia directa en 18 países.

Teva Pharmaceutical Industries posee 19 subsidiarias incluyendo Medis Germany, Pliva y Teva ANZ.

Ver el organigrama con sus 45 ejecutivos principales

Biografías más buscadas en Teva Europe

• Juan Ibarra, General Manager, Spain & Portugal
• Nikolay Hadjidontchev, General Manager, Bulgaria and Greece
• Juha-Matti Korajoki, Senior Director and Head,Central Nervous Syst...

Crear su alerta
para seguir los movimientos de los ejecutivos en Teva Europe.

Teva Pharmaceutical Industries tiene 1.837 competidores entre los que se incluyen Pfizer (Estados Unidos), Johnson & Johnson (Estados Unidos) y Sanofi (Francia).

Popular M&A news in Farmacia

• Supernus Pharmaceuticals has announced the acquisition of Sage Therapeutics  (publicado el 16 de junio de 2025).
• Juvenescence acaba de anunciar una recaudación de fondos de 76 millones de dólares. (publicado el 22 de mayo de 2025).
• Kincell Bio acaba de anunciar una recaudación de fondos de 22 millones de dólares. (publicado el 22 de mayo de 2025).

Otros contactos sugeridos en el sector Farmacia

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets en Bristol-Myers Squibb
• Amanda Moore - Vice President, Program Leadership and Clinical Operations en Abeona Therapeutics
• Keiichi Ando - Independent Non-Executive Director en Shionogi

Saber más sobre el sector Farmacia

Últimos comunicados de prensa de Teva Europe

• Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients
• Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease
• Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan
• Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025
• Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference
• Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan
• Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients
• Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
• Teva Statement on European Commission Decision; Company to Appeal
• Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.
• View more press releases Close

Redes sociales sobre Teva Europe

• Teva Europe en Wikipedia, Google News y Yahoo Finance
• Teva Europe en LinkedIn, Twitter y YouTube